Advertisement

Chronic Kidney Disease in the Transgender, Nonbinary, or Gender Diverse Person

  • David Collister
    Correspondence
    Address reprint requests to David Collister, MD, PhD, Division of Nephrology, University of Alberta, 11-113H Clinical Sciences Building, Edmonton, Alberta, Canada.
    Affiliations
    Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada

    Population Health Research Institute, Hamilton, Ontario, Canada
    Search for articles by this author
  • Yonah Krakowsky
    Affiliations
    Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada

    Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada

    Department of Surgery, Women's College Hospital, Toronto, Ontario, Canada
    Search for articles by this author
  • Emery Potter
    Affiliations
    Department of Surgery, Women's College Hospital, Toronto, Ontario, Canada

    Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada
    Search for articles by this author
  • Adam C. Millar
    Affiliations
    Division of Endocrinology and Metabolism, Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada

    Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Search for articles by this author

      Summary

      Nephrologists are increasingly providing care to transgender, nonbinary, and gender diverse (TNBGD) individuals with chronic kidney disease. This narrative review discusses the care of TNBGD individuals from a nephrology perspective. TNBGD individuals are under-represented in the nephrology literature. TNBGD individuals are at an increased risk of adverse outcomes compared with the cisgender population including mental health, cardiovascular disease, malignancy, sexually transmitted infections, and mortality. Gender-affirming hormone therapy (GAHT) with estradiol in transfeminine individuals potentially increases the risk of venous thromboembolism and cardiovascular disease. GAHT with testosterone in transmasculine individuals potentially increases the risk of erythrocytosis and requires careful monitoring. GAHT modifies body composition and lean muscle mass, which in turn influence creatinine generation and excretion, which may impact the performance of estimated glomerular filtration rate (GFR) equations and the estimation of 24-hour urine values from spot urine albumin/protein to creatinine ratios. There are limited studies regarding TNBGD individuals with chronic kidney disease. Additional research is needed to evaluate the effects of GAHT on GFR and biomarkers of kidney function and the performance of the estimated GFR equation in TNBGD populations.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Reisner SL
        • Poteat T
        • Keatley J
        • et al.
        Global health burden and needs of transgender populations: a review.
        Lancet. 2016; 388: 412-436https://doi.org/10.1016/s0140-6736(16)00684-x
        • Clayton JA
        • Tannenbaum C.
        Reporting sex, gender, or both in clinical research?.
        JAMA. 2016; 316: 1863-1864https://doi.org/10.1001/jama.2016.16405
        • Soldin OP
        • Mattison DR.
        Sex differences in pharmacokinetics and pharmacodynamics.
        Clin Pharmacokinet. 2009; 48: 143-157https://doi.org/10.2165/00003088-200948030-00001
        • Bartz D
        • Chitnis T
        • Kaiser UB
        • et al.
        Clinical advances in sex- and gender-informed medicine to improve the health of all: a review.
        JAMA Intern Med. 2020; 180: 574-583https://doi.org/10.1001/jamainternmed.2019.7194
        • Mauvais-Jarvis F
        • Bairey Merz N
        • Barnes PJ
        • et al.
        Sex and gender: modifiers of health, disease, and medicine.
        Lancet. 2020; 396: 565-582https://doi.org/10.1016/S0140-6736(20)31561-0
        • Safer JD
        • Tangpricha V.
        Care of transgender persons.
        N Engl J Med. 2019; 381: 2451-2460https://doi.org/10.1056/NEJMcp1903650
        • Liszewski W
        • Peebles JK
        • Yeung H
        • Arron S
        Persons of nonbinary gender - awareness, visibility, and health disparities.
        N Engl J Med. 2018; 379: 2391-2393https://doi.org/10.1056/NEJMp1812005
        • Meerwijk EL
        • Sevelius JM.
        Transgender population size in the United States: a meta-regression of population-based probability samples.
        Am J Public Health. 2017; 107: e1-e8https://doi.org/10.2105/ajph.2016.303578
        • Collin L
        • Reisner SL
        • Tangpricha V
        • Goodman M.
        Prevalence of transgender depends on the “case” definition: a systematic review.
        J Sex Med. 2016; 13: 613-626https://doi.org/10.1016/j.jsxm.2016.02.001
        • Downing JM
        • Przedworski JM.
        Health of transgender adults in the U.S., 2014-2016.
        Am J Prev Med. 2018; 55: 336-344https://doi.org/10.1016/j.amepre.2018.04.045
        • Collister D
        • Pyne L
        • Bhasin A
        • et al.
        Sex and gender considerations in randomized controlled trials in adults receiving chronic dialysis published in high impact journals: a meta-epidemiologic study.
        Abstract, Canadian Society of Nephrology Annual General Meeting, May. 2022;
        • Smyth B
        • Haber A
        • Trongtrakul K
        • et al.
        Representativeness of randomized clinical trial cohorts in end-stage kidney disease: a meta-analysis.
        JAMA Intern Med. 2019; 179: 1316-1324https://doi.org/10.1001/jamainternmed.2019.1501
        • Laprise C
        • Cole K
        • Sridhar VS
        • et al.
        Sex and gender considerations in transplant research: a scoping review.
        Transplantation. 2019; 103: e239-e247https://doi.org/10.1097/TP.0000000000002828
        • Tahhan AS
        • Vaduganathan M
        • Greene SJ
        • et al.
        Enrollment of older patients, women, and racial/ethnic minority groups in contemporary acute coronary syndrome clinical trials: a systematic review.
        JAMA Cardiol. 2020; 5: 714-722https://doi.org/10.1001/jamacardio.2020.0359
        • Tahhan AS
        • Vaduganathan M
        • Greene SJ
        • et al.
        Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review.
        JAMA Cardiol. 2018; 3: 1011-1019https://doi.org/10.1001/jamacardio.2018.2559
        • Jin X
        • Chandramouli C
        • Allocco B
        • Gong E
        • Lam CSP
        • Yan LL.
        Women's participation in cardiovascular clinical trials from 2010 to 2017.
        Circulation. 2020; 141: 540-548https://doi.org/10.1161/circulationaha.119.043594
        • Van Spall HG
        • Toren A
        • Kiss A
        • Fowler RA.
        Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review.
        JAMA. 2007; 297: 1233-1240https://doi.org/10.1001/jama.297.11.1233
        • White Hughto JM
        • Reisner SL
        • Pachankis JE.
        Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions.
        Soc Sci Med. 2015; 147: 222-231https://doi.org/10.1016/j.socscimed.2015.11.010
        • Wierckx K
        • Elaut E
        • Declercq E
        • et al.
        Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study.
        Eur J Endocrinol. 2013; 169: 471-478https://doi.org/10.1530/EJE-13-0493
        • Getahun D
        • Nash R
        • Flanders WD
        • et al.
        Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study.
        Ann Intern Med. 2018; 169: 205-213https://doi.org/10.7326/m17-2785
        • Dragon CN
        • Guerino P
        • Ewald E
        • Laffan AM.
        Transgender Medicare beneficiaries and chronic conditions: exploring fee-for-service claims data.
        LGBT Health. 2017; 4: 404-411https://doi.org/10.1089/lgbt.2016.0208
        • Scandurra C
        • Mezza F
        • Maldonato NM
        • et al.
        Health of non-binary and genderqueer people: a systematic review.
        Front Psychol. 2019; 10: 1453https://doi.org/10.3389/fpsyg.2019.01453
        • Townsend M
        • Jaffer H
        • Goldman L.
        Adverse health outcomes in transgender people.
        CMAJ. 2017; 189: E1046
        • Levey AS
        • Becker C
        • Inker LA.
        Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review.
        JAMA. 2015; 313: 837-846https://doi.org/10.1001/jama.2015.0602
      1. James SE, Herman JL, Rankin S, et al. The report of the 2015 U.S. transgender survey. Accessed November 18, 2021. https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report-Dec17.pdf

        • Shatzel JJ
        • Connelly KJ
        • DeLoughery TG.
        Thrombotic issues in transgender medicine: a review.
        Am J Hematol. 2017; 92: 204-208https://doi.org/10.1002/ajh.24593
        • Lam JSH
        • Abramovich A.
        Transgender-inclusive care.
        CMAJ. 2019; 191: E79https://doi.org/10.1503/cmaj.180954
        • Arnold LM.
        Promoting culturally competent care for the lesbian, gay, bisexual, and transgender population.
        Am J Public Health. 2001; 91: 1731
        • Baral SD
        • Poteat T
        • Strömdahl S
        • Wirtz AL
        • Guadamuz TE
        • Beyrer C.
        Worldwide burden of HIV in transgender women: a systematic review and meta-analysis.
        Lancet Infect Dis. 2013; 13: 214-222https://doi.org/10.1016/s1473-3099(12)70315-8
        • Connelly PJ
        • Marie Freel E
        • Perry C
        • et al.
        Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults.
        Hypertension. 2019; 74: 1266-1274https://doi.org/10.1161/hypertensionaha.119.13080
        • Edmiston EK
        • Donald CA
        • Sattler AR
        • Peebles JK
        • Ehrenfeld JM
        • Eckstrand KL.
        Opportunities and gaps in primary care preventative health services for transgender patients: a systemic review.
        Transgend Health. 2016; 1: 216-230https://doi.org/10.1089/trgh.2016.0019
        • Hembree WC
        • Cohen-Kettenis PT
        • Gooren L
        • et al.
        Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2017; 102: 3869-3903https://doi.org/10.1210/jc.2017-01658
        • Costa R
        • Colizzi M.
        The effect of cross-sex hormonal treatment on gender dysphoria individuals' mental health: a systematic review.
        Neuropsychiatr Dis Treat. 2016; 12: 1953-1966https://doi.org/10.2147/ndt.s95310
        • Nobili A
        • Glazebrook C
        • Arcelus J.
        Quality of life of treatment-seeking transgender adults: a systematic review and meta-analysis.
        Rev Endocr Metab Disord. 2018; 19: 199-220https://doi.org/10.1007/s11154-018-9459-y
        • White Hughto JM
        • Reisner SL.
        A systematic review of the effects of hormone therapy on psychological functioning and quality of life in transgender individuals.
        Transgend Health. 2016; 1: 21-31https://doi.org/10.1089/trgh.2015.0008
        • Scheim AI
        • Bauer GR.
        Sex and gender diversity among transgender persons in Ontario, Canada: results from a respondent-driven sampling survey.
        J Sex Res. 2015; 52: 1-14https://doi.org/10.1080/00224499.2014.893553
        • Deutsch MB
        • Bhakri V
        • Kubicek K.
        Effects of cross-sex hormone treatment on transgender women and men.
        Obstet Gynecol. 2015; 125: 605-610https://doi.org/10.1097/aog.0000000000000692
        • Defreyne J
        • Vantomme B
        • Van Caenegem E
        • et al.
        Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence.
        Andrology. 2018; 6: 446-454https://doi.org/10.1111/andr.12485
        • Tangpricha V
        • den Heijer M.
        Oestrogen and anti-androgen therapy for transgender women.
        Lancet Diabetes Endocrinol. 2017; 5: 291-300https://doi.org/10.1016/s2213-8587(16)30319-9
        • Chan W
        • Drummond A
        • Kelly M.
        Deep vein thrombosis in a transgender woman.
        CMAJ. 2017; 189 (E502-E504)https://doi.org/10.1503/cmaj.160408
        • de Blok CJM
        • Wiepjes CM
        • Nota NM
        • et al.
        Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands.
        BMJ. 2019; 365: l1652https://doi.org/10.1136/bmj.l1652
        • Joint R
        • Chen ZE
        • Cameron S.
        Breast and reproductive cancers in the transgender population: a systematic review.
        BJOG. 2018; 125: 1505-1512https://doi.org/10.1111/1471-0528.15258
        • Canner JK
        • Harfouch O
        • Kodadek LM
        • et al.
        Temporal trends in gender-affirming surgery among transgender patients in the United States.
        JAMA Surg. 2018; 153: 609-616https://doi.org/10.1001/jamasurg.2017.6231
        • Jun MS
        • Santucci RA.
        Urethral stricture after phalloplasty.
        Transl Androl Urol. 2019; 8: 266-272https://doi.org/10.21037/tau.2019.05.08
        • Shoureshi P
        • Dugi 3rd, D
        Penile inversion vaginoplasty technique.
        Urol Clin North Am. 2019; 46: 511-525https://doi.org/10.1016/j.ucl.2019.07.006
        • Buncamper ME
        • van der Sluis WB
        • van der Pas RSD
        • et al.
        Surgical outcome after penile inversion vaginoplasty: a retrospective study of 475 transgender women.
        Plast Reconstr Surg. 2016; 138: 999-1007https://doi.org/10.1097/PRS.0000000000002684
        • Bairey Merz CN
        • Dember LM
        • Ingelfinger JR
        • et al.
        Sex and the kidneys: current understanding and research opportunities.
        Nat Rev Nephrol. 2019; 15: 776-783https://doi.org/10.1038/s41581-019-0208-6
        • Nitsch D
        • Grams M
        • Sang Y
        • et al.
        Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis.
        BMJ. 2013; 346: f324https://doi.org/10.1136/bmj.f324
        • Jafar TH
        • Schmid CH
        • Stark PC
        • et al.
        The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
        Nephrol Dial Transplant. 2003; 18: 2047-2053https://doi.org/10.1093/ndt/gfg317
        • Neugarten J
        • Acharya A
        • Silbiger SR.
        Effect of gender on the progression of nondiabetic renal disease: a meta-analysis.
        J Am Soc Nephrol. 2000; 11: 319-329
        • Neugarten J
        • Golestaneh L.
        Gender and the prevalence and progression of renal disease.
        Adv Chronic Kidney Dis. 2013; 20: 390-395https://doi.org/10.1053/j.ackd.2013.05.004
        • Monster TB
        • Janssen WM
        • de Jong PE
        • de Jong-van den Berg LT.
        Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria.
        Arch Intern Med. 2001; 161: 2000-2005https://doi.org/10.1001/archinte.161.16.2000
        • Ahmed SB
        • Hovind P
        • Parving HH
        • et al.
        Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy.
        Diabetes Care. 2005; 28: 1988-1994https://doi.org/10.2337/diacare.28.8.1988
        • Burgner A
        • Hladunewich MA.
        Contraception and CKD.
        Clin J Am Soc Nephrol. 2020; 15: 563-565https://doi.org/10.2215/cjn.09770819
        • Ramesh S
        • Mann MC
        • Holroyd-Leduc JM
        • et al.
        Hormone therapy and clinical and surrogate cardiovascular endpoints in women with chronic kidney disease: a systematic review and meta-analysis.
        Menopause. 2016; 23: 1028-1037https://doi.org/10.1097/gme.0000000000000657
        • Ahmed SB
        • Culleton BF
        • Tonelli M
        • et al.
        Oral estrogen therapy in postmenopausal women is associated with loss of kidney function.
        Kidney Int. 2008; 74: 370-376https://doi.org/10.1038/ki.2008.205
        • Kattah AG
        • Suarez MLG
        • Milic N
        • et al.
        Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis.
        Menopause. 2018; 25: 625-634https://doi.org/10.1097/gme.0000000000001062
        • Fung MM
        • Poddar S
        • Bettencourt R
        • Jassal SK
        • Barrett-Connor E.
        A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: the Rancho Bernardo Study.
        Menopause. 2011; 18: 629-637https://doi.org/10.1097/gme.0b013e3181fca9c4
        • Khurana KK
        • Navaneethan SD
        • Arrigain S
        • Schold JD
        • Nally Jr., JV
        • Shoskes DA
        Serum testosterone levels and mortality in men with CKD stages 3-4.
        Am J Kidney Dis. 2014; 64: 367-374https://doi.org/10.1053/j.ajkd.2014.03.010
        • Handelsman DJ.
        Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation.
        Endocr Rev. 1985; 6: 151-182https://doi.org/10.1210/edrv-6-2-151
        • Singh AB
        • Norris K
        • Modi N
        • et al.
        Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.
        J Clin Endocrinol Metab. 2001; 86: 2437-2445https://doi.org/10.1210/jcem.86.6.7525
        • Chiang JM
        • Kaysen GA
        • Segal M
        • Chertow GM
        • Delgado C
        • Johansen KL.
        Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis.
        Nephrol Dial Transplant. 2019; 34: 802-810https://doi.org/10.1093/ndt/gfy252
        • Yilmaz MI
        • Sonmez A
        • Qureshi AR
        • et al.
        Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease.
        Clin J Am Soc Nephrol. 2011; 6: 1617-1625https://doi.org/10.2215/cjn.10681210
        • Kyriazis J
        • Tzanakis I
        • Stylianou K
        • et al.
        Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients.
        Nephrol Dial Transplant. 2011; 26: 2971-2977https://doi.org/10.1093/ndt/gfq847
        • Carrero JJ
        • Qureshi AR
        • Nakashima A
        • et al.
        Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease.
        Nephrol Dial Transplant. 2011; 26: 184-190https://doi.org/10.1093/ndt/gfq397
        • Gungor O
        • Kircelli F
        • Carrero JJ
        • et al.
        Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging?.
        Clin J Am Soc Nephrol. 2010; 5: 2018-2023https://doi.org/10.2215/cjn.03600410
        • Carrero JJ
        • Qureshi AR
        • Parini P
        • et al.
        Low serum testosterone increases mortality risk among male dialysis patients.
        J Am Soc Nephrol. 2009; 20: 613-620https://doi.org/10.1681/asn.2008060664
        • Bello AK
        • Stenvinkel P
        • Lin M
        • et al.
        Serum testosterone levels and clinical outcomes in male hemodialysis patients.
        Am J Kidney Dis. 2014; 63: 268-275https://doi.org/10.1053/j.ajkd.2013.06.010
        • Lapi F
        • Azoulay L
        • Niazi MT
        • Yin H
        • Benayoun S
        • Suissa S.
        Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
        JAMA. 2013; 310: 289-296https://doi.org/10.1001/jama.2013.8638
        • Spanos C
        • Bretherton I
        • Zajac JD
        • Cheung AS.
        Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: a systematic review.
        World J Diabetes. 2020; 11: 66-77https://doi.org/10.4239/wjd.v11.i3.66
        • Klaver M
        • Dekker M
        • de Mutsert R
        • Twisk JWR
        • den Heijer M.
        Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis.
        Andrologia. 2017; 49https://doi.org/10.1111/and.12660
        • Collister D
        • Krupka E
        • et al.
        The impact of gender affirming hormone therapy on kidney function biomarkers and glomerular filtration rate: a systematic review and meta-analysis.
        Abstract, Canadian Society of Nephrology Annual General Meeting, May. 2022;
        • Ginsburg ES
        • Owen Jr., WF
        • Greenberg LM
        • Shea BF
        • Lazarus JM
        • Walsh BW
        Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease.
        J Clin Endocrinol Metab. 1996; 81: 4414-4417https://doi.org/10.1210/jcem.81.12.8954051
        • Stehman-Breen C
        • Anderson G
        • Gibson D
        • Kausz AT
        • Ott S
        Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis.
        Kidney Int. 2003; 64: 290-294https://doi.org/10.1046/j.1523-1755.2003.00073.x
        • Molnar AO
        • Bota SE
        • McArthur E
        • et al.
        Risk and complications of venous thromboembolism in dialysis patients.
        Nephrol Dial Transplant. 2018; 33: 874-880https://doi.org/10.1093/ndt/gfx212
        • Asscheman H
        • Giltay EJ
        • Megens JA
        • de Ronde WP
        • van Trotsenburg MA
        • Gooren LJ.
        A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
        Eur J Endocrinol. 2011; 164: 635-642https://doi.org/10.1530/eje-10-1038
        • Go AS
        • Chertow GM
        • Fan D
        • McCulloch CE
        • Hsu CY.
        Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
        N Engl J Med. 2004; 351: 1296-1305https://doi.org/10.1056/NEJMoa041031
        • Kapoor P
        • Luttrell BM
        • Williams D.
        The free androgen index is not valid for adult males.
        J Steroid Biochem Mol Biol. 1993; 45: 325-326https://doi.org/10.1016/0960-0760(93)90350-6
        • Levey AS
        • Bosch JP
        • Lewis JB
        • Greene T
        • Rogers N
        • Roth D.
        A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.
        Ann Intern Med. 1999; 130 (doi:199903160-00002): 461-470
        • Bachman E
        • Travison TG
        • Basaria S
        • et al.
        Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point.
        J Gerontol A Biol Sci Med Sci. 2014; 69: 725-735https://doi.org/10.1093/gerona/glt154
        • Ponce OJ
        • Spencer-Bonilla G
        • Alvarez-Villalobos N
        • et al.
        The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: a systematic review and meta-analysis of randomized, placebo-controlled trials.
        J Clin Endocrinol Metab. Mar 17 2018; https://doi.org/10.1210/jc.2018-00404
        • Quach K
        • Lvtvyn L
        • Baigent C
        • et al.
        The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis.
        Am J Kidney Dis. 2016; 68: 591-598https://doi.org/10.1053/j.ajkd.2016.04.011
        • Cockcroft DW
        • Gault MH.
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41https://doi.org/10.1159/000180580
        • Inker LA
        • Schmid CH
        • Tighiouart H
        • et al.
        Estimating glomerular filtration rate from serum creatinine and cystatin C.
        N Engl J Med. 2012; 367: 20-29https://doi.org/10.1056/NEJMoa1114248
        • Fan L
        • Levey AS
        • Gudnason V
        • et al.
        Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals.
        J Am Soc Nephrol. 2015; 26: 1982-1989https://doi.org/10.1681/asn.2014060607
        • Stevens LA
        • Claybon MA
        • Schmid CH
        • et al.
        Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating the glomerular filtration rate in multiple ethnicities.
        Kidney Int. 2011; 79: 555-562https://doi.org/10.1038/ki.2010.462
        • Inker LA
        • Levey AS
        • Tighiouart H
        • et al.
        Performance of glomerular filtration rate estimating equations in a community-based sample of Blacks and Whites: the multiethnic study of atherosclerosis.
        Nephrol Dial Transplant. 2018; 33: 417-425https://doi.org/10.1093/ndt/gfx042
        • Leung TK
        • Luk AO
        • So WY
        • Lo MK
        • Chan JC.
        Development and validation of equations estimating glomerular filtration rates in Chinese patients with type 2 diabetes.
        Kidney Int. 2010; 77: 729-735https://doi.org/10.1038/ki.2009.549
        • Chen YW
        • Chen HH
        • Wang TE
        • Chang CW
        • Wu CJ.
        Difference between CKD-EPI and MDRD equations in calculating glomerular filtration rate in patients with cirrhosis.
        World J Gastroenterol. 2011; 17: 4532-4538https://doi.org/10.3748/wjg.v17.i40.4532
        • Gagneux-Brunon A
        • Delanaye P
        • Maillard N
        • et al.
        Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort.
        AIDS. 2013; 27: 1573-1581https://doi.org/10.1097/QAD.0b013e32835fac30
        • Shaffi K
        • Uhlig K
        • Perrone RD
        • et al.
        Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients.
        Am J Kidney Dis. 2014; 63: 1007-1018https://doi.org/10.1053/j.ajkd.2014.01.436
        • Delanaye P.
        Creatinine-based GFR estimating equations in kidney transplant recipients.
        Am J Kidney Dis. 2014; 64: 818https://doi.org/10.1053/j.ajkd.2014.05.027
        • Levey AS
        • Inker LA.
        GFR evaluation in living kidney donor candidates.
        J Am Soc Nephrol. 2017; 28: 1062-1071https://doi.org/10.1681/asn.2016070790
        • Price CP
        • Newall RG
        • Boyd JC.
        Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review.
        Clin Chem. 2005; 51 (doi:clinchem.2005.049742): 1577-1586
        • Grubbs V.
        Precision in GFR reporting: let's stop playing the race card.
        Clin J Am Soc Nephrol. 2020; 15: 1201-1202https://doi.org/10.2215/cjn.00690120
        • Levey AS
        • Titan SM
        • Powe NR
        • Coresh J
        • Inker LA.
        Kidney disease, race, and GFR estimation.
        Clin J Am Soc Nephrol. 2020; 15: 1203-1212https://doi.org/10.2215/cjn.12791019
        • Hughes JP
        • Emel L
        • Hanscom B
        • Zangeneh S.
        Design issues in transgender studies.
        J Acquir Immune Defic Syndr. 2016; 72: S248-S251https://doi.org/10.1097/qai.0000000000001077
        • Owen-Smith AA
        • Woodyatt C
        • Sineath RC
        • et al.
        Perceptions of barriers to and facilitators of participation in health research among transgender people.
        Transgend Health. 2016; 1: 187-196https://doi.org/10.1089/trgh.2016.0023
        • Fredriksen-Goldsen KI
        • Kim HJ
        • McKenzie GL
        • Krinsky L
        • Emlet CA.
        Plan of action for real-world translation of LGBTQ health and aging research.
        LGBT Health. 2017; 4: 384-388https://doi.org/10.1089/lgbt.2017.0185
        • Siskind RL
        • Andrasik M
        • Karuna ST
        • et al.
        Engaging transgender people in NIH-funded HIV/AIDS clinical trials research.
        J Acquir Immune Defic Syndr. 2016; 72: S243-S247https://doi.org/10.1097/qai.0000000000001085